Podcasts about loncar investments

Brad Loncar Biography Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. He's also the co-host of Biotech Clubhouse, which recaps the week's biotech news every Sunday at 4pm EST. On this episode we discussed with Brad: How he first became interested in China biopharma and his advice for getting ‘smart' on the industry as a foreign investor. Key players in the China biopharma ecosystem, including investors as well as founder and company profiles How investors should think about regulatory and geopolitical risk when it comes to investing in China biotech

Brad Loncar is a Biotechnology expert, a pioneer in Biotech investment, and the index provider for two Nasdaq-listed biotech ETFs, Loncar's Cancer Immunotherapy ETF, and the China BioPharma ETF.  Brad is CEO of Loncar Investments and has a wealth of investment experience, having started out at Franklin Templeton as part of their Management Training Program. Brad's also spent time in the US political sphere, having been appointed Senior Advisor at the U.S. Department of the Treasury, in between an Investment Directorship in the Bush-Cheney administration in 2004, and a short tenure as Director of Administration for John McCain, in 2008.  Brad currently shares his expertise on LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. We discuss the rampant innovation transforming a constantly evolving industry, before examining Loncar's two unique ETFs. We finish the interview by looking ahead, where Brad highlights his favourite innovations at the cutting-edge of Biotechnology. Enjoy!Thanks to Cofruition for consulting on and producing the podcast. Want further Opto insights? Check out our daily newsletter: https://www.cmcmarkets.com/en-gb/opto/newsletter

The FDA has approved Biogen's (BIIB) Alzheimer's drug. Brad Loncar, CEO of Loncar Investments, talks about the impact of the Biogen drug approval as well as the recent activity in the health care sector. He also discusses how Biogen's treatment compares to others in the pipeline and what he believes is the next catalyst in the health care sector. Tune in to find out more.

Matt discusses one of his favorite long-term investment opportunities of a lifetime - Chinese Biotech. Brad Loncar of Loncar Investments joins Matt to talk about the booming biotech sector in China. Brad is the creator of the index that the China BioPharma ETF (CHNA) tracks. Brad shares his thoughts on a few stocks in the ETF and why he is so bullish on the sector. Matt also delves into the genetic testing sector and how it is the keystone to the future of health care.

John Authers, Senior Editor for Bloomberg Markets, on why bond proxies aren't as safe as they appear. Brooke Sutherland, Deals and Industrials Columnist for Bloomberg Opinion, on Deere earnings and why GE left itself open to Markopolos' critique. Brad Loncar, CEO of Loncar Investments, on why investors should be looking at China biotech. David Katz, President and CIO of Matrix Asset Advisors, on why he's buying the dip. Hosted by Lisa Abramowicz and Paul Sweeney.

In this first episode, I sat down with Brad Loncar to talk about the China biotech sector and more: - How did Brad get into biotech investing? - What are the differences between the U.S. and China biotech sector? How will HKEx and Shanghai's tech board reshape the IPO market? - How will China's drug pricing reforms impact global drug prices? - What is the 4+7 procurement pilot program? Are Chinese pharmas shifting towards innovation? - How will the ongoing trade war impact the industry? What is Brad's long term outlook for China biotech?

In this week’s episode of Industry Focus: Healthcare, Shannon Jones and special guest Simon Erickson, sit down with Brad Loncar, CEO of Loncar Investments, to discuss China’s biotech revolution. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

GEN Sounds of Science July 18, 2017 Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

GEN Sounds of Science March 9, 2017 Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”?

A new class of immunotherapies is promising to radically alter the treatment of cancers and has generated excitement among investors for their groundbreaking potential. Now the Loncar Cancer Immunotherapy ETF provides a way for investors to bet on the sector through an exchange traded fund that consists of both Big Pharma and emerging growth biotechs leading the sector. We spoke to Brad Loncar, CEO of Loncar Investments and creator of the ETF, about the fund, why the focus on this narrow slice of the biotech world, and why he thinks immunotherapies will dramatically reshape cancer care in the years ahead.